<DOC>
	<DOC>NCT00772551</DOC>
	<brief_summary>Evaluation of the pharmacokinetics and safety of raltegravir and ezetimibe when co-administered to male and female healthy volunteers.</brief_summary>
	<brief_title>Raltegravir and Ezetimibe PK Study</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements Male or nonpregnant, nonlactating females Between 18 to 65 years, inclusive Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month after the study Any significant acute or chronic medical illness Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations Positive blood screen for hepatitis B and/or C antibodies Positive blood screen for HIV1 and 2 antibodies Current or recent (within 3 months) gastrointestinal disease Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, followup procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study Exposure to any investigational drug or placebo within 4 weeks of first dose of study drug Consumption of grapefruit, or Seville oranges or any grapefruit or Seville orange containing product within one week of first dose of study drug and for the duration of the study Use of any other drugs, including overthecounter medications and herbal preparations, within two weeks prior to first dose of study drug, unless approved/prescribed by the Principal Investigator as known not to interact with study drugs. Females of childbearing potential without the use of effective nonhormonal birth control methods, or not willing to continue practising these birth control methods for at least 30 days after the end of the treatment period Previous allergy to any of the constituents of the pharmaceuticals administered in this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>